



# FORMULATING THE RESEARCH QUESTION

Eric van Roon – September 29 2017 – EAHP Academy Seminar

**mcl**  
medisch centrum  
leeuwarden



university of  
groningen



# CONFLICT OF INTEREST

THERE ARE NO CONFLICTS OF INTEREST TO DECLARE

# QUESTIONS

1. Yes or no: the 'research question' concerns the question whether or not to proceed with the proposed study?

2. Yes or no: quality control of a proposed research question is possible

MC: Which part of the final scientific publication is most likely to contain the answer to the research question?

1. Methods
2. Table 1
3. Figure 1


# MAKING CHOICES.....





# THE -RATIONS OF SCIENTIFIC RESEARCH





# RESEARCH: 5 STEPS

T  
H  
I  
N  
K  
I  
N  
G  
  
D  
O  
I  
N  
G

1. What is the reason why I want to answer which research question?
2. How do I want to answer the research question?
  - Variables
  - Operationalisation of variables
  - Study design (RCT, observational)
  - Population (number, in- and exclusion)
3. Study conduct
4. Datavalidation and –analysis
5. Reporting and presentation

# THE 'THINKING' - PHASE

Why which research question?

- What?
- Why?

Introduction section of protocol/report/publication

- Rationale
- Goal


Operationalisation

- How?
- Methods section of protocol/report/publication



# STEP 1 – THE RESEARCH QUESTION

What do I want to know, and why?



# STEP 1 – THE RESEARCH QUESTION



# STEP 1 – THE RESEARCH QUESTION

*keep it simple*



# **‘HOW’ VERSUS ‘WHAT’**



# HOW: MEASURING TOOL

Key aspects of a measuring tool

Sensitive for change?

Validated?

Reproducible?

Relevant?

# HOW: SENSITIVITY OF THE MEASURING TOOL

For example:


Measuring an inflammatory state

Options:

- C-reactive protein (CRP)
- Erythrocyte sedimentation rate (ESR)

CRP: quick with a high amplitude

ESR: slow with low amplitude





# HOW: VALIDATION OF THE MEASURING TOOL

For example:


Peripheral neuropathy in multiple myeloma

Options:

- Electromyography (EMG)
- ICPN Questionnaire

EMG: one fibre or muscle, invasive; reflects presence of peripheral neuropathy?

ICPN-Q: holistic determination, including ADL; validated for MM.



# HOW: REPRODUCIBILITY OF THE TOOL

For example:

Measuring 'hoarding' (OCD in DSM V)



# HOW: REPRODUCIBILITY OF THE TOOL

## Clutter Image Rating: Bedroom

Please select the photo that most accurately reflects the amount of clutter in your room.



1



2



3



4



5



6



7



8



9

# WHAT? THE RESEARCH QUESTION AN EXAMPLE

## **Prophylactic Intravenous Ondansetron and Dolasetron in Intrathecal Morphine-Induced Pruritus: A Randomized, Double-Blinded, Placebo-Controlled Study**

Christos A. Iatrou, MD, PhD, Christos K. Dragoumanis, MD,  
Theodosia D. Vogiatzaki, MD, PhD, George I. Vretzakis MD, PhD,  
Constantinos E. Simopoulos, MD, PhD, and Vasilios K. Dimitriou, MD, PhD

Departments of Anesthesia and Surgery, Democritus University of Thrace, Alexandroupolis, Greece, and the Department of Anesthesia, "G. Gennimatas" Hospital, Athens, Greece

Anesth Analg 2005;101:1516–20



Intrathecal morphine improves postoperative analgesia, but it is accompanied by a frequent incidence of postoperative nausea and vomiting (PONV) and pruritus (1). Pruritus is the most common side effect of intrathecal morphine, with a reported incidence of 62% to 94% (2–4). It is unpleasant for patients and difficult to treat, and its prevention remains a challenge for anesthesiologists (5,6). Although the exact mechanism is unclear, it seems that intrathecal morphine's interaction with central 5-hydroxytryptamine subtype 3 (5-HT<sub>3</sub>) receptors (6) plays some role in the genesis of pruritus. As a result, 5-HT<sub>3</sub> receptor antagonists could be effective in its control. Ondansetron has been used for this purpose with conflicting results (3,4,7,8). Dolasetron, another 5-HT<sub>3</sub> receptor antagonist, is usually used to control nausea and vomiting associated with chemotherapy and PONV (9,10). However, its antipruritic activity has not been evaluated. Therefore, we conducted a prospective, randomized, double-blind, placebo-controlled study to determine the effectiveness of dolasetron and ondansetron for the prevention of pruritus after spinal anesthesia performed with bupivacaine and morphine in patients undergoing elective vascular, orthopedic, or urologic surgery.

The clinical problem

The rationale for this Rx

The study goal /  
research question

# COMPONENTS OF THE RESEARCH QUESTION

Therefore, we conducted a prospective, randomized, double-blind, placebo-controlled study to determine the effectiveness of **dolasetron and ondansetron** for the prevention of pruritus after spinal anesthesia performed with bupivacaine and morphine in patients undergoing elective vascular, orthopedic, or urologic surgery.

## Determinant

The effect of ....

Independent variable

X-axis



# COMPONENTS OF THE RESEARCH QUESTION

Therefore, we conducted a prospective, randomized, double-blind, placebo-controlled study to determine the effectiveness of dolasetron and ondansetron

the prevention of pruritus after spinal anesthesia performed with bupivacaine and morphine undergoing elective vascular, orthopedic, or urologic surgery.

**End point**

... on ...

Dependent variable

Y-axis

# COMPONENTS OF THE RESEARCH QUESTION

Therefore, we conducted a prospective, randomized, double-blind, placebo-controlled study to determine the effectiveness of dolasetron and ondansetron for the prevention of pruritus after spinal anesthesia performed with bupivacaine and morphine in patients undergoing elective vascular, orthopedic, or urologic surgery.

Domain

... in ...

Population

# THE RESEARCH QUESTION: OVERVIEW

## Determinant

The effect of ....

Independent variable

X-axis

## End point

... on ...

Dependent variable

Y-axis

## Domain

... in ...

Population

# COMPARE PICO-MODELL IN EBM

P: POPULATION = DOMAIN

I: INTERVENTION = DETERMINANT

C: CONTROL = PLACEBO


O: OUTCOME = END POINT

# RESEARCH QUESTION: THE ESSENTIALS

1. CLEAR
2. FOCUS
3. RECOGNIZABLE ELEMENTS
  - DETERMINANT, END POINT, DOMAIN
4. CONSISTENT USE IN
  - TITLE
  - OBJECTIVE
  - FIGURE 1 OR TABLE 2

# RESEARCH QUESTION QUALITY CHECK

*Pray such on all a  
done not with brown  
but halfse or ve  
of so. In imp ren  
funt when was am  
how for do ren  
dunt or a cat  
Gross just under my  
pigeon that a boy  
about 20m  
muffled her own thing*



**Fig. 1** Position of model penguin during defaecation and physical parameters used to calculate rectal pressure necessary to expel faecal material over a distance of 40 cm

1. DRAW PRIMARY FIGURE OR TABLE IN DEVELOPMENT PHASE
2. IF NOT POSSIBLE: INSUFFICIENTLY DEVELOPED RESEARCH QUESTION



# BACK TO OUR EXAMPLE

**Table 2.** Incidence of the Pruritus and Postoperative Nausea and Vomiting, Sum of Pain Visual Analogue Scale Scores for Observations in Postanesthesia Care Unit, 2, 4, 8, and 24 h, Rescue Meperidine Delivered by Patient-Controlled Analgesia for 24 h

	Placebo ( <i>n</i> = 35)	Dolasetron ( <i>n</i> = 35)	Ondansetron ( <i>n</i> = 35)
Incidence of pruritus*	23/35 (66%)	7/35 (20%)‡	12/35 (34%)§
95% CI	51% to 81%	8% to 32%	18% to 50%
Males	14/20 (70%)	3/18 (18%)	5/19 (26%)
Females	9/15 (60%)	4/17 (29%)	7/16 (44%)
Incidence of PONV†	15/35 (43%)	6/35 (17%)	8/35 (23%)
95% CI	27% to 59%	5% to 29%	9% to 37%
Sum of pain VAS scores (cm)	5.5 ± 2.5	4.9 ± 2.3	5.7 ± 2.5
Rescue meperidine (mg)	17.1 ± 13.8	13.4 ± 13.9	16.3 ± 12.1

Values are number of patients (%) or mean ± SD.

PONV = postoperative nausea and vomiting; VAS = visual analog scale; PACU = postanesthesia care unit; CI = confidence interval.

\*  $P < 0.01$ ; †  $P < 0.05$  when compared with chi-square test; ‡  $P < 0.001$ ; §  $P < 0.01$  when compared to placebo with chi-square test.

# KEY MESSAGES

- Scientific research and its 4 –rations
- Discriminate between ‘what’ and ‘how’
- The essentials of a research question are
  - DETERMINANT
  - END POINT
  - DOMAIN
- Draw a figure or table based on virtual data as a quality check
- Be consistent in using the essentials of the research question in Title, Goal, Rationale and Figure 1 /Table 2.

THANKS FOR YOUR ATTENTION  
QUESTIONS?

**mcl**  
■ medisch centrum  
leeuwarden



university of  
groningen



# QUESTIONS & ANSWERS

1. Yes or no: the 'research question' concerns the question whether or not to proceed with the proposed study?

- No, the research question concerns the question on which the proposed study will provide the answer.

2. Yes or no: quality control of a proposed research question is possible

- Yes, by checking whether or not the researcher can draw Figure 1 or Table 2 on basis of virtual data.

33. MC: Which part of the final scientific publication is most likely to contain the answer to the research question?

1. Methods
2. Table 1
3. Figure 1